Listened to the above webinar which mostly went above my head. One thought that was triggered from that discussion is that Race may initiate some work to develop a biomarker tool to identify patients who may benefit from including Zantrene along with the anthracyclines for better cardio-protection. That way it can only be administered to patients who can benefit from it rather than everyone undergoing anthracycline treatments.
As a separate thought, could patients undergoing radiation therapy and at risk of cardio toxicity be given Zantrene for cardio protection?
Listened to the above webinar which mostly went above my head....
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.035(2.11%) |
Mkt cap ! $276.9M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.62 | $172.5K | 105.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5995 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 4075 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |